DnB Asset Management AS Acquires 2,685 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

DnB Asset Management AS raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 35,804 shares of the biopharmaceutical company's stock after acquiring an additional 2,685 shares during the quarter. DnB Asset Management AS's holdings in Regeneron Pharmaceuticals were worth $25,504,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. State Street Corp raised its position in shares of Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock valued at $5,153,603,000 after purchasing an additional 61,277 shares during the period. Loomis Sayles & Co. L P grew its stake in Regeneron Pharmaceuticals by 33.4% in the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock valued at $1,122,168,000 after buying an additional 393,997 shares during the last quarter. Amundi raised its holdings in Regeneron Pharmaceuticals by 45.8% in the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after acquiring an additional 487,489 shares during the period. Norges Bank acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth $802,036,000. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company's stock valued at $495,639,000 after purchasing an additional 22,538 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several equities analysts recently weighed in on REGN shares. Truist Financial cut their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating for the company in a research report on Wednesday, January 8th. Wells Fargo & Company lowered their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a research note on Friday, January 10th. Sanford C. Bernstein decreased their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 7th. UBS Group lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their price objective for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Finally, Bank of America reissued an "underperform" rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $966.88.

Regeneron Pharmaceuticals Trading Up 1.3 %

Shares of NASDAQ REGN traded up $8.03 during midday trading on Wednesday, hitting $625.03. The stock had a trading volume of 478,439 shares, compared to its average volume of 677,063. The firm has a market cap of $68.33 billion, a P/E ratio of 16.33, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $607.72 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The company's 50-day simple moving average is $681.52 and its 200 day simple moving average is $788.06.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. During the same period in the previous year, the business posted $11.86 EPS. The company's quarterly revenue was up 10.3% compared to the same quarter last year. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.56%. Regeneron Pharmaceuticals's payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.